

2013

« 2 (. . . -), 5/7.

HYPERTENSION IN 2013

E.M. Dolya

SUMMARY

Currently arterial hypertension (AH) remains an important issue of cardiology. Increase of blood pressure (BP) causes such serious complications as myocardial infarction and stroke. New aspects of Recommendations for AH in 2013 have a focus on measuring BP. In 2013 Recommendations for AH, renovated stratification of the general cardio-vascular risks is presented. Considerable changes have appeared in antihypertensive therapy prescription. Contemporary recommendations solve many problems, yet they put new issues to be investigated, perhaps, the solutions will be presented in the next version of the recommendations.

2013

2013 () 2013

35% - 20 ()

[2]. - 10 ()

10 . . . [11].

30%, - [14].

2013 ()

10 . . . () [8].

[5].

40

II.

(.2).

[9].

[12].

2

	-
	- , , II
	, -
	- , II
	- , II
	-
	, - , II
	,
	- , II, , ,
()	II, - , ,
	,
/	- , II
	- ,
) (,
	- , II,
	- , II
	, ,

14%

50%. 10%

[6].

1.

[3]:

: 1

140-160

?

2. — // 2010. — 1. — : “ » . 13-15.

3. 7. Bobrie G. Masked hypertension: a systematic review. / Bobrie G, Clerson P, Menard J et all. // J Hypertens. – 2008. – Vol. 26. – P.1715 –1725.

4. 8. Clark C.E. Association of a difference in systolic blood pressure between arms with vascular disease and mortality: a systematic review and meta-analysis./ Clark C.E., Taylor R.S., Shore A.C. et all // Lancet. – 2012. – Vol. 379. – P. 905 –914.

5. 9. Corrao G. Reduced discontinuation of anti-hypertensive treatment by two-drug combination as first step. Evidence from daily life practice. / Corrao G., Parodi A., Zambon A. et all.// J Hypertens. – 2010. – Vol. 28. – P. 1584 –1590.

6. 10. Fagard R.H. Incidence of cardiovascular events in white-coat, masked and sustained hypertension vs. true normotension: a meta-analysis / Fagard R.H., Cornelissen V.A. // J Hypertens. – 2007. – Vol. 25. – P.2193 –2198.

7. 11. Fagard R.H. Orthostatic hypotension is a more robust predictor of cardiovascular events than nighttime reverse dipping in elderly / Fagard R.H., De Cort P. // Hypertension. – 2010. – Vol. 56. – P. 56-61.

8. 12. Gupta A.K. Compliance, safety and effectiveness of fixeddose combinations of antihypertensive agents: a meta-analysis. / Gupta A.K., Arshad S., Poulter N.R. // Hypertension. – 2010. – Vol. 55. – P. 399 –407.

9. 13. 2013 ESH/ESC Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) European Heart Journal. – 2013. – Vol. 34. – P. 2159-2219.

10. 14. Julius S. Usefulness of heart rate to predict cardiac events in treated patients with high-risk systemic hypertension /Julius S., Palatini P., Kjeldsen S.E. et al. // Am. J. Cardiol. – 2012. – Vol. 109. – P. 685-692.

11. 15. Jordan J. Joint statement of the European Association for the Study of Obesity and the European Society of Hypertension: obesity and difficult to treat arterial hypertension. / Jordan J., Yumuk V., Schlaich M. et. all // J Hypertens. – 2012. – Vol. 30. – P.1047 –1055.

12. 16. Ogedegbe G. Masked hypertension: evidence of the need to treat. / Ogedegbe G., Agyemang C., Ravenell J.E. // Current Hypertens Rep. – 2010. – Vol. 12. – P. 349 –355.

13. 17. Rossi A. The impact of physical activity on mortality in patients with high blood pressure: a systematic review. / Rossi A., Dikareva A., Bacon S.L. et all. // J Hypertens. – 2012. – Vol. 30. – P. 1277 – 1288.

14. 18. Schmieder RE ESH position paper: renal denervation: an interventional therapy of resistant hypertension. // Schmieder R.E., Redon J., Grassi G. et all. // Hypertens.- 2012.- Vol. 30. – P. 837–841.

15. 19. Simplicity HTN-1 Investigators. Catheter-based

[3].

1. . . . ESH/ESC 2013 / . . . // “ . . . 2013. – 6. – . - . 10-11.

2. . . . / . . . : http://www.apteka.ua/article/233241.

3. . . . 2013 . / . . . // . . . - 2013. - 1. - . : « . . . » . - . 9-25.

4. . . . / . . . ” . . . ” . — 2010. — 1. — : « . . . » . - . 3-12.

5. . . . / . . . , . . . / . . . -2013.- 1.- 20.- : « . . . » . - . 58-62.

6. . . . :

renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months. // *Hypertension*. – 2011. – Vol. 57. – P. 911–917.

20. Simplicity HTN-Investigators. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial):

a randomised controlled trial // *Lancet*. – 2010. – Vol. 376. – P. 1903 – 1909.

21. Stessen M. The effect of coffee consumption on blood pressure and the development of hypertension: a systematic review and meta-analysis. / Stessen M., Kuhle C., Hensrad D. et al. // *J Hypertens*. – 2012. – Vol. 30. – P. 2245 –2254.